» Articles » PMID: 36563842

Deferasirox Alleviates DSS-induced Ulcerative Colitis in Mice by Inhibiting Ferroptosis and Improving Intestinal Microbiota

Overview
Journal Life Sci
Publisher Elsevier
Date 2022 Dec 23
PMID 36563842
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) caused by multiple factors. Studies have shown that epithelial cell damage was associated with ferroptosis in UC. Therefore, our research focused on the effects and mechanism of iron chelator deferasirox in UC.

Main Methods: The UC model was induced by 2.5 % dextran sulfate sodium salt (DSS) and administered with deferasirox (10 mg/kg) for 7 days. Histological pathologies, inflammatory response, ferrous iron contents, oxidative stress and ferroptosis regulators were determined. Intestinal microbiota alteration and short-chain fatty acids (SCFAs) production were analyzed through 16S rRNA gene sequencing and targeted metabolomics.

Key Findings: Deferasirox significantly relieved the DSS-induced UC in mice, as evidenced by weight loss, survival rate, colon length shortening disease activity index (DAI) score and histology score. Deferasirox treatment reduced the level of pro inflammatory cytokines (IL-1β, IL-6, TNF-α and INF-γ). Ferroptosis was induced in mice with UC, as evidenced by ferrous iron accumulation, increased ROS production, SOD and GSH depletion, decreased the expression of GPX-4 and FTH, accompanied by increased expression of TF. Deferasirox treatment strongly reversed the alterations caused by ferroptotic characteristics in DSS-induced mice. Moreover, deferasirox treatment reshaped the composition of intestinal microbiota. The results revealed the genera of norank_f__Muribaculaceae, Lachnospiraceae_NK4A136_group, Prevotellaceae_UCG-001, Odoribacter and Blautia were increased distinctly, while Escherichia-Shigella and Streptococcus were significantly decreased by deferasirox treatment. Targeted metabolomics analysis indicated the SCFAs production enhanced in deferasirox-treated mice.

Significance: Our results suggested that deferasirox could treat DSS-induced UC in mice by inhibiting ferroptosis and improving intestinal microbiota.

Citing Articles

Gut metabolites and functional recovery after ischemic stroke: a genetic perspective.

Wu W, Zhu L, Zhang J, Li X, Yu D, Wang Y Mamm Genome. 2025; .

PMID: 40056206 DOI: 10.1007/s00335-025-10120-4.


Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma.

Li B, Liu S, Zhou X, Hou D, Jia H, Tang R Int J Mol Sci. 2025; 26(4).

PMID: 40003990 PMC: 11855378. DOI: 10.3390/ijms26041524.


Three signalling pathways for iron overload in osteoporosis: a narrative review.

Zou L, Chen G, Rong Y, Tang C, Lv X, Fan Y J Orthop Surg Res. 2025; 20(1):186.

PMID: 39979989 PMC: 11844007. DOI: 10.1186/s13018-025-05588-4.


Phase-dependent iron depletion differentially regulates the niche of intestinal stem cells in experimental colitis via ERK/STAT3 signaling pathway.

Wang S, Liu X, Xu L, Lang J, Liu D Front Immunol. 2025; 16:1537651.

PMID: 39949764 PMC: 11822217. DOI: 10.3389/fimmu.2025.1537651.


Treatment of Acute Ulcerative Colitis with Zinc Hyaluronate in Mice.

Zhang L, Fu X, Li J, Xiao W, Xiong X, Lv H J Microbiol Biotechnol. 2025; 35:e2408050.

PMID: 39947703 PMC: 11876020. DOI: 10.4014/jmb.2408.08050.